 |
市場調查報告書
商品編碼
2148317
下一代細胞療法市場：按細胞類型、療法類型、來源、應用、最終用戶和地區分類Next Generation Cell Therapy Market, By Cell Type, By Therapy Type, By Source, By Application, By End User, By Geography |
||||||
價格
簡介目錄
預計到2026年，下一代細胞療法市場規模將達到74億美元，到2033年將達到358.8億美元。預計從2026年到2033年，其複合年成長率將達到25.3%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 74億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 25.30% | 2033年市場規模預測： | 358.8億美元 |
全球新一代細胞療法市場涵蓋了利用活細胞修復、替換或再生受損組織以及治療複雜疾病的先進療法。這些療法包括CAR-T細胞療法、NK細胞療法、iPS細胞衍生療法和基因編輯細胞療法，並應用於腫瘤學、自體免疫疾病、心血管疾病和罕見遺傳疾病等廣泛領域。
合成生物學、基於CRISPR的基因組編輯以及細胞製造技術的進步，正推動這些療法從研究階段走向臨床和商業應用。同時，監管支持的加強、生產規模的提升以及對先進細胞技術投資的增加，正進一步加速全球下一代細胞療法的研發和應用。
市場動態
全球新一代細胞療法市場的發展動力源自於癌症和慢性病發病率的上升、基因修飾細胞療法臨床療效的不斷提高，以及CRISPR-Cas9和鹼基編輯等基因編輯技術的進步。此外，監管支持的加強、政府資金的投入以及同種異體「現成」療法的開發，也加速了商業化進程，並擴大了患者的治療選擇範圍。
然而，該市場面臨許多限制因素，包括高昂的製造成本、複雜的個人化生產、冷鏈要求以及嚴格的品管。儘管如此，在生物技術、製藥和研究機構之間合作日益密切的推動下，同種異體細胞療法、人工智慧驅動的生產和患者篩選，以及在固體癌、自體免疫疾病和神經系統疾病等領域的拓展應用，都蘊藏著巨大的發展機會。
本次調查的主要特點
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據以下參數，對全球下一代細胞療法市場中的關鍵公司進行了概況介紹：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
- 這份「全球下一代細胞療法市場」報告的目標受群眾外包括產業內的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以利用分析全球下一代細胞療法市場中使用的各種策略矩陣來促進決策。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章：市場動態、監管與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 監管趨勢
- 細胞類型發布/批准
- PEST分析
- 波特的分析
- 市場機遇
- 產業趨勢
第4章 全球下一代細胞療法市場：依細胞類型分類，2021-2033年
- T細胞
- 自然殺手（NK）細胞
- 幹細胞
- 樹突狀細胞
- 巨噬細胞
- 其他
第5章 全球下一代細胞療法市場：依療法類型分類，2021-2033年
- CAR-T細胞療法
- T細胞受體（TCR）療法
- 腫瘤浸潤淋巴細胞（TIL）療法
- CAR-NK細胞療法
- 幹細胞療法
- 其他
第6章 全球下一代細胞療法市場：依來源分類，2021-2033年
- 本土種植
- 同種
第7章 全球下一代細胞療法市場：依應用領域分類，2021-2033年
- 骨髓惡性腫瘤
- 固體癌
- 自體免疫疾病
- 遺傳性疾病
- 神經病變
- 其他
第8章 全球下一代細胞療法市場：以最終用戶分類，2021-2033年
- 醫院和癌症中心
- 製藥和生物技術公司
- 合約研發生產組織（CDMO）
- 學術研究機構
- 專業細胞治療中心
- 其他
第9章 全球下一代細胞療法市場：按地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第10章 競爭格局
- Novartis AG
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- Johnson & Johnson
- Legend Biotech Corporation
- Autolus Therapeutics plc
- Iovance Biotherapeutics, Inc.
- Adaptimmune Therapeutics plc
- Allogene Therapeutics, Inc.
- CRISPR Therapeutics AG
第11章 分析師建議
- 機會分析
- 分析師意見
- Coherent Opportunity Map
第12章 參考文獻與調查方法
- 參考
- 調查方法
- 關於本公司
簡介目錄
Product Code: CMI10150
Next Generation Cell Therapy Market is estimated to be valued at USD 7.40 Bn in 2026 and is expected to reach USD 35.88 Bn by 2033, growing at a compound annual growth rate (CAGR) of 25.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 7.40 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 25.30% | 2033 Value Projection: | USD 35.88 Bn |
The global next generation cell therapy market encompasses advanced therapies that utilize living cells to repair, replace or regenerate damaged tissues and treat complicated diseases. These therapies include CAR-T, NK cell, iPSC-derived and gene edited cell therapies with applications across oncology, auto-immune disorders, cardiovascular diseases and rare genetic conditions.
Advances in synthetic biology, CRISPR-based genome engineering and cell manufacturing are driving these therapies from research to clinical and commercial applications, while increasing regulatory support, improving manufacturing scalability and increased investment in advanced cellular technologies are further accelerating the development and adoption of next generation cell therapies globally.
Market Dynamics
The global next generation cell therapy market is driven by the increasing incidence of cancer and chronic diseases, increasing clinical validation of engineered cell therapies and advancements in gene-editing technologies such as CRISPR-Cas9 and base editing. Increasing regulatory support, government funding and development of allogeneic "off-the-shelf" therapies are other factors that are accelerating commercialization and expanding patient accessibility.
However, a number of constraints are present in the market, such as high manufacturing costs, complex personalized production, cold-chain requirements and stringent quality controls. Nevertheless, significant opportunities exist within allogeneic cell therapies, AI-enabled manufacturing and patient selection and expansion into solid tumors, autoimmune diseases and neurological disorders supported by increasing collaboration across biotechnology, pharmaceutical and research organizations.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global next generation cell therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Johnson & Johnson, Legend Biotech Corporation, Autolus Therapeutics plc, Iovance Biotherapeutics, Inc., Adaptimmune Therapeutics plc, Allogene Therapeutics, Inc., and CRISPR Therapeutics AG
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global next generation cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global next generation cell therapy market
Market Segmentation
- Cell Type Insights (Revenue, USD Bn, 2021 - 2033)
- T Cells
- Natural Killer (NK) Cells
- Stem Cells
- Dendritic Cells
- Macrophages
- Others
- Therapy Type Insights (Revenue, USD Bn, 2021 - 2033)
- CAR-T Cell Therapy
- T-Cell Receptor (TCR) Therapy
- Tumor-Infiltrating Lymphocyte (TIL) Therapy
- CAR-NK Cell Therapy
- Stem Cell Therapy
- Others
- Source Insights (Revenue, USD Bn, 2021 - 2033)
- Autologous
- Allogeneic
- Application Insights (Revenue, USD Bn, 2021 - 2033)
- Hematological Malignancies
- Solid Tumors
- Autoimmune Diseases
- Genetic Disorders
- Neurological Disorders
- Others
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals and Cancer Centers
- Pharmaceutical and Biotechnology Companies
- Contract Development and Manufacturing Organizations (CDMOs)
- Academic and Research Institutes
- Specialized Cell Therapy Centers
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis AG
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- Johnson & Johnson
- Legend Biotech Corporation
- Autolus Therapeutics plc
- Iovance Biotherapeutics, Inc.
- Adaptimmune Therapeutics plc
- Allogene Therapeutics, Inc.
- CRISPR Therapeutics AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Next Generation Cell Therapy Market, By Cell Type
- Global Next Generation Cell Therapy Market, By Therapy Type
- Global Next Generation Cell Therapy Market, By Source
- Global Next Generation Cell Therapy Market, By Application
- Global Next Generation Cell Therapy Market, By End User
- Global Next Generation Cell Therapy Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Cell Type Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Industry Trends
4. Global Next Generation Cell Therapy Market, By Cell Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- T Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Natural Killer (NK) Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Stem Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Dendritic Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Macrophages
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Next Generation Cell Therapy Market, By Therapy Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- CAR-T Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- T-Cell Receptor (TCR) Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Tumor-Infiltrating Lymphocyte (TIL) Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- CAR-NK Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Stem Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Next Generation Cell Therapy Market, By Source, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Autologous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Allogeneic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Next Generation Cell Therapy Market, By Application, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hematological Malignancies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Solid Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Autoimmune Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Genetic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
8. Global Next Generation Cell Therapy Market, By End User, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals and Cancer Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Pharmaceutical and Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Contract Development and Manufacturing Organizations (CDMOs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Specialized Cell Therapy Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
9. Global Next Generation Cell Therapy Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Cell Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Source, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Cell Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Source, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Cell Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Source, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Cell Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Source, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Cell Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Source, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Cell Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Source, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Novartis AG
- Company Highlights
- Cell Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Cell Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences, Inc.
- Company Highlights
- Cell Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Cell Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Legend Biotech Corporation
- Company Highlights
- Cell Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Autolus Therapeutics plc
- Company Highlights
- Cell Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Iovance Biotherapeutics, Inc.
- Company Highlights
- Cell Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Adaptimmune Therapeutics plc
- Company Highlights
- Cell Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allogene Therapeutics, Inc.
- Company Highlights
- Cell Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- CRISPR Therapeutics AG
- Company Highlights
- Cell Type Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
02-2729-4219
+886-2-2729-4219
細胞蛋白原料市場：全球市場預測（2026-2032年）
全球基因和細胞治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）全球過繼性細胞療法市場規模、佔有率、趨勢和成長分析報告（2026-2034年）
體內細胞療法市場規模、佔有率和趨勢分析報告：按治療細胞類型、治療應用、體內細胞工程、給藥方法、地區和細分市場預測（2026-2033 年）2026-2034年全球細胞治療用人類成分市場規模、佔有率、趨勢和成長分析報告自動化和封閉式細胞治療市場：策略分析和預測（2026-2031 年）
細胞療法市場分析及預測（至2035年）：按類型、產品、服務、技術、組件、應用、過程、最終用戶、解決方案和階段2026-2034年細胞療法包裝全球市場規模、佔有率、趨勢和成長分析報告細胞療法市場：按類型、治療方法、給藥途徑、應用和最終用戶分類－2026-2032年全球市場預測細胞療法包裝市場規模、佔有率和趨勢分析報告：按包裝類型、材料、細胞療法類型、地區和細分市場預測（2026-2033 年）
▼